DSpace Repository

Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi.

Show simple item record

dc.contributor Médecins sans Frontières, Thyolo District, Thyolo, Malawi.
dc.creator Moses, M
dc.creator Zachariah, R
dc.creator Tayler-Smith, K
dc.creator Misinde, D
dc.creator Foncha, C
dc.creator Manzi, M
dc.creator Bauerfeind, A
dc.creator Mwagomba, B
dc.creator Kwanjana, J
dc.creator Harries, A D
dc.date 2010-02
dc.date.accessioned 2017-01-31T07:16:27Z
dc.date.available 2017-01-31T07:16:27Z
dc.identifier Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi. 2010, 14 (2):197-202 Int. J. Tuberc. Lung Dis.
dc.identifier 1815-7920
dc.identifier 20074411
dc.identifier http://hdl.handle.net/10144/95554
dc.identifier http://fieldresearch.msf.org/msf/handle/10144/95554
dc.identifier The International Journal of Tuberculosis and Lung Disease : the official journal of the International Union against Tuberculosis and Lung Disease
dc.identifier.uri http://dspace.mediu.edu.my:8181/xmlui/handle/10144/95554
dc.description SETTING: Thyolo District Hospital, rural Malawi. OBJECTIVES: To report on 1) clinical, immunological and virological outcomes and 2) safety among human immunodeficiency virus (HIV) infected patients with tuberculosis (TB) who received concurrent nevirapine (NVP) and rifampicin (RMP) based treatment. DESIGN: Retrospective cohort study. METHODS: Analysis of programme data, June-December 2007. RESULTS: Of a total of 156 HIV-infected TB patients who started NVP-based antiretroviral treatment, 136 (87%) completed TB treatment successfully, 16 (10%) died and 5 (4%) were transferred out. Mean body weight and CD4 gain (adults) were respectively 4.4 kg (95%CI 3.3-5.4) and 140 cells/mm(3) (95%CI 117-162). Seventy-four per cent of patients who completed TB treatment and had a viral load performed (n = 74) had undetectable levels (<50 copies/ml), while 17 (22%) had a viral load of 50-1000 copies/ml. Hepatotoxicity was present in 2 (1.3%) patients at baseline. Two patients developed Grade 2 and one developed Grade 3 alanine transaminase enzyme elevations during TB treatment (incidence rate per 10 years of follow-up 4.2, 95%CI 1.4-13.1). There were no reported deaths linked to hepatotoxicity. CONCLUSIONS: In a rural district in Malawi, concomitant NVP and RMP treatment is associated with good TB treatment outcomes and appears safe. Further follow-up of patients would be useful to ascertain the longer-term effects of this concurrent treatment.
dc.language en
dc.rights Archived with thanks to The International Journal of Tuberculosis and Lung Disease : the official journal of the International Union against Tuberculosis and Lung Disease
dc.title Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi.


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account